Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

71 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a Phase IB/II, two-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab + paclitaxel + novel oncology therapies (i.e. therapies designed for immune modulation) and durvalumab + paclitaxel alone as first-line treatment in patients with metastatic triple negative breast cancer (TNBC).

The purpose of this study is to assess the efficacy and safety of pembrolizumab vsersus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized, phase II/III trial studies how well standard-of-care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard-of-care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to determine if the study drug talazoparib (also called BMN 673) is safe when given as a breast cancer treatment and to evaluate how cancer responds to it.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide are more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) (the “study drug”) with two approved drugs (capecitabine and trastuzumab) in participants with advanced breast cancer to find out what effects, good or bad, it may have on the participants and their disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 3 multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body.